Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

SELLAS Life Sciences Group, Inc. Director's Dealing 2011

Apr 22, 2011

33651_dirs_2011-04-22_1963c3cd-6fcb-423d-a1db-88c39b6ff72e.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: RXI PHARMACEUTICALS CORP (RXII)
CIK: 0001390478
Period of Report: 2011-04-13

Reporting Person: Kennedy Robert Eugene (Vice President and CFO)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2011-04-13 Common Stock A 374288 Acquired 374288 Direct
2011-04-13 Common Stock A 2430 Acquired 376718 Indirect
2011-04-13 Common Stock A 2576 Acquired 379294 Indirect

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2011-04-13 Stock Option $1.275 A 30000 Acquired 2021-04-12 Common Stock (30000) Direct

Footnotes

F1: Received in exchange for 3,078,013 shares of Apthera, Inc. common stock in connection with merger of Apthers, Inc. into RXI Pharmaceuticals Corporation (the "Merger"). On the effective date of the Merger, the closing price of RXI Pharmaceuticals Corporation common stock was $1.275 per share.

F2: Received in exchange for 20,000 shares of Apthera, Inc. common stock in connection with merger of Apthers, Inc. into RXI Pharmaceuticals Corporation (the "Merger"). On the effective date of the Merger, the closing price of RXI Pharmaceuticals Corporation common stock was $1.275 per share.

F3: The reporting person is a managing member of the LLC that owns the reporting securities. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

F4: Received in exchange for 21,200 shares of Apthera, Inc. common stock in connection with merger of Apthers, Inc. into RXI Pharmaceuticals Corporation (the "Merger"). On the effective date of the Merger, the closing price of RXI Pharmaceuticals Corporation common stock was $1.275 per share.

F5: Granted pursuant to the RXi Pharmaceuticals Corporation 2007 Incentive Plan.

F6: Per share.

F7: 1,250 of the options vested on July 13, 2011, with the remaining shares vesting in equal installments on each of the next 11 quarterly anniversaries of July 13, 2011.